Thermo Fisher Scientific Inc. (TMO)
| Market Cap | 193.58B |
| Revenue (ttm) | 44.56B |
| Net Income (ttm) | 6.70B |
| Shares Out | 371.48M |
| EPS (ttm) | 17.74 |
| PE Ratio | 29.37 |
| Forward PE | 21.23 |
| Dividend | $1.72 (0.33%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 2,030,768 |
| Open | 515.73 |
| Previous Close | 520.12 |
| Day's Range | 509.48 - 521.28 |
| 52-Week Range | 385.46 - 643.99 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 639.83 (+22.78%) |
| Earnings Date | Jan 29, 2026 |
About TMO
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and... [Read more]
Financial Performance
In 2025, Thermo Fisher's revenue was $44.56 billion, an increase of 3.91% compared to the previous year's $42.88 billion. Earnings were $6.70 billion, an increase of 5.82%.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for TMO stock is "Strong Buy." The 12-month stock price target is $639.83, which is an increase of 22.78% from the latest price.
News
Thermo Fisher Scientific Introduces New Laboratory Developed Test to Help Transplant Patients Receive the Right Dose of Critical Anti-Rejection Medication Sooner
WEST HILLS, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TacroType™ Pharmacogenetic Test, a new laboratory developed test d...
Thermo Fisher Scientific Increases Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0....
Thermo Fisher Scientific to Present at Raymond James Annual Institutional Investors Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will pr...
5 Oversold Stocks to Buy Before They Rebound
In this episode of The Morning Filter, co-hosts Dave Sekera and Susan Dziubinski unpack what the Supreme Court's ruling on the Trump Administration's emergency tariffs may mean for markets. They also ...
Thermo Fisher Scientific Expands Real-World Data Interoperability and Linkage Through Strategic Collaboration with Datavant
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with Datavant, the data collaboration platform trusted fo...
Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of $3.8 billion aggregate principal amount (the “Offering”) ...
Thermo Fisher: The Market Is Missing The Point, This Pullback Is A Buy (Rating Update)
Thermo Fisher delivered strong Q1 results, beating expectations with revenue of $12.21B (+7% YoY) and EPS of $6.57 (+8%). I reaffirm my strong buy rating on TMO, setting a target price of $668 per sha...
Thermo Fisher Scientific Inc. (TMO) Q4 2025 Earnings Call Transcript
Thermo Fisher Scientific Inc. (TMO) Q4 2025 Earnings Call Transcript
Thermo Fisher Scientific Discloses How Much Clario Deal Could Add To Its EPS
Thermo Fisher Scientific Inc. (NYSE: TMO) on Thursday reported fourth-quarter 2025 adjusted earnings of $6.57 per share, beating the street view of $6.45.
Thermo Fisher beats quarterly results estimates on demand for tools from pharma clients
Thermo Fisher Scientific on Thursday beat Wall Street estimates for fourth-quarter profit and revenue on strong demand for its tools and services used in drug development by pharmaceutical clients.
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended Decembe...
Thermo Fisher Scientific Inc. (TMO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Thermo Fisher Scientific Inc. (TMO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Thermo Fisher wins contracts as pharma shifts production to US, CEO says
Thermo Fisher Scientific's pharmaceutical services business has won a number of contracts to help its customers move production from Europe or Asia to the U.S., the medical equipment maker's CEO, Marc...
Nalgene Outdoor Unveils Thrill & Motion: A High-Energy Color Collection for 2026
ROCHESTER, N.Y.--(BUSINESS WIRE)--Nalgene Outdoor today introduces Thrill & Motion, a dynamic new collection crafted for people who embrace an active, on-the-go lifestyle; whether exploring trails, ch...
Thermo Fisher Scientific Announces Strategic Collaboration With NVIDIA Leveraging AI to Advance Scientific Instrumentation and Accelerate Laboratory Performance
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced a strategic collaboration with NVIDIA to power AI-based solutions and laborat...
Thermo Fisher Chief Operating Officer Michel Lagarde Leaving Company
Thermo Fisher Scientific's number-two executive, Michel Lagarde, is leaving the life-sciences giant to pursue another opportunity.
Thermo Fisher Scientific to Present at the J.P. Morgan 2026 Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will pr...
Thermo Fisher Scientific Launches CorEvitas Obesity Registry to Advance Real-World Evidence in Treatment Outcomes
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific launches CorEvitas Obesity Registry to advance real-world evidence in treatment outcomes.
Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 29, 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full ye...
Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer's Disease Registry to Advance Real-World Evidence in Neurodegenerative Care
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer's Disease Registry to Advance Real-World Evidence in Neurodegenerative Care.
OlivePoint Capital Acquires 3900 Paramount Parkway in Raleigh–Durham, Expanding Its High-Conviction Office Special Situations Strategy
LOS ANGELES--(BUSINESS WIRE)--OlivePoint acquires a Class A Raleigh office 100% leased to PPD/Thermo Fisher, highlighting its strategy to target mispriced, credit-backed assets.
Thermo Fisher Scientific Expands Gibco™ Bacto™ Portfolio with Next-Generation, Chemically Defined Media to Boost E. coli Biomanufacturing Productivity
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Gibco™ Bacto™ CD Supreme FPM Plus and Gibco™ Bacto™ CD Supreme Feed (...
Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack
The Investment Committee debate the latest Calls of the Day.
Thermo Fisher Scientific Deepens Investment in Asia's Biopharma Ecosystem with Expansion of Bioprocess Design Centers
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitm...
Top 15 High-Growth Dividend Stocks For December 2025
The Top 15 High-Growth Dividend Stocks for December 2025 offer a 1.58% yield and 20.97% five-year dividend growth, appearing 33% undervalued. The watchlist's goal is a 12% long-term CAGR, with Novembe...